A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals

HIV Clinical Trials

Volumn 11, Issue 2, 2010, Pages 80-99

  Kühne, Felicitas ^a   Chancellor, Jeremy ^a   Mollon, Patrick ^b   Myers, Daniela ^c   Louie, Michael ^c   Powderly, William ^d  

^a Health Economics and Outcomes Research   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

AIDS; Anti HIV agents; Cost effectiveness; Economic model; HIV; Monte Carlo method

Indexed keywords

MARAVIROC;

ADD ON THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; VIROGENESIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, CCR5; TRIAZOLES; VIRAL TROPISM;

EID: 77953571602     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1102-80     Document Type: Article

References (61)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13): 853-860.
2. Hellinger FJ. The lifetime cost of treating a person with HIV. J Am Med Assoc. 1993;270(4):474-478.
3. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodefi ciency virus care in the United States. Med Care. 2006;44(11):990-997.
4. Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS. 2008;22(1):89-95.
5. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831. (Pubitemid 32222162)
6. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002;162(21):2478-2486.
7. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfi navir as the fi rst-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294-304.
8. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134(6): 440-450.
9. Chan DC, Kim PS. HIV entry and its inhibition. Cell. 1998;93(5):681-684.
10. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998;280(5371):1884-1888.
11. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429-1441.
12. Hardy D, Reynes J, Konourina I, et al. Effi cacy and safety of maraviroc plus optimized background therapy in treatment- experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. Presented at: 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston, MA. Abstract of poster presentation 792.
13. Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997;12(1):54-66.
14. Hornberger J, Kilby JM, Wintfeld N, Green J. Costeffectiveness of enfuvirtide in HIV therapy for treatmentexperienced patients in the United States. AIDS Res Hum Retroviruses. 2006;22(3):240-247.
15. Richter A, Hauber B, Simpson K, Mauskopf JA, Yin D. A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens. Pharmacoeconomics. 2002;20(4): 215-224.
16. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39(1):69-77.
17. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodefi ciency virus (HIV) infection. Ann Intern Med. 1991;114(9):798-802.
18. Multicenter AIDS Cohort Study (MACS) Public Data Set: Release P04. Springfi eld, VA: National Technical Information Service; 1995.
19. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodefi ciency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158(7):687-694.
20. d'Arminio MA, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165(4): 416-423.
21. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954.
22. Chancellor J, Kuehne FC, Weinstein M, Mollon P. Microsimulation or cohort modeling? A comparative case study in HIV infection. Presented at: ISPOR 12th Annual International Meeting; 2007; Arlington, VA. Abstract of poster presentation PIN36, p. A170.
23. Kühne F, Chancellor J, Weinstein M, Mollon P. Microsimulation versus cohort modelling of antiretroviral therapy in treatment-naive and treatment-experienced populations. Presented at: Health Technology Assessment International (HTAi) IV Annual Meeting; 2007; Barcelona. Abstract of poster presentation M67.
24. Kühne F, Chancellor J, Mollon P, Powderly WG. Microsimulation or cohort modelling? A comparative case study in HIV based on treatment experienced patients. Presented at: International Health Economic Association (iHEA) 6th World Congress on Health Economics; 2007; Copenhagen. Abstract of poster presentation T82.
25. Pfi zer Inc. Selzentry (maraviroc). Prescribing information (US Label). 2007.
26. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ. 2005;14(8):763-776.
27. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc; 1987:166-167.
28. Henry K, Tebas P, Lane C. Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. J Am Med Assoc. 2006;296(12):1523-1525.
29. Arias E. United States Life Tables, 2003. National Vital Statistics Reports, vol.54 no.14. Hyattsville, MD: National Center for Health Statistics; 2006.
30. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfi navir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345(6):398-407.
31. Baxter JD, Mayers DL, Wentworth DN, et al. A rondomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14(9):F83-F93.
32. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. J Am Med Assoc. 2006;296(7):769-781.
33. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodefi ciency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733.
34. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis. 2006;42(6):870-877.
35. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16(2):201-207.
36. US Public Health Service and the Infectious Diseases Society of America. Guidelines for the prevention of opportunistic infections among HIV-infected persons - 2002. June 14, 2002. Available at: http://www.aidsinfo.nih.gov/ default. aspx.
37. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: US Department of Health and Human Services; 2008:1-128.
38. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP, Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994 June 15;51(12):1555-1563
39. Paltiel AD, Scharfstein JA, Seage GR III, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998;18(2 Suppl):S93-105.
40. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22(1):27-38.
41. Drug Topic. Red Book. Montvale, NJ: 2006.
42. US Department of Labor Bureau of Labor Statistics. Available at: http:www.bls.gov/cpi/cpi-dr.htm. Accessed May 2008.
43. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115-1128.
44. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903-912.
45. Wu AW, Reviski DA, Jacobson DL, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
46. Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in Health and Medicine. New York: Oxford University Press; 1996.
47. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999;131(3):194-198.
48. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfi navir as the fi rst-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294-304.
49. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9): 1441-1449.
50. Elbasha EE, Szucs T, Chaudhary MA, et al. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clin Trials. 2009;10(4):233-253.
51. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defi c Syndr. 2005;38(4):382-392.
52. van der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials. In: Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract H-715.
53. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. J Am Med Assoc.1998;279(2):130-136.
54. Freedberg KA, Hirschhorn LR, Schackman BR, et al. Costeffectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defi c Syndr. 2006;43(Suppl 1):S113-S118.
55. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodefi ciency virus infection. Am J Med. 2003;115(8):632-641.
56. Kimmel AD, Goldie SJ, Walensky RP, et al. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005;10(1):41-52.
57. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316-1323.
58. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001;91(9):1456-1463.
59. Asmuth D, Goodrich J, Cooper D, et al. CD4+ cell restoration after 48 weeks in the maraviroc (MVC) treatmentexperienced (TE) trials MOTIVATE 1 and 2. In: Program and abstracts of the Annual XVII International AIDS Conference; 2008; Mexico. Abstract of poster presentation TUPE0050.
60. Nelson M, Arasteh K, Clotet B, et al. Durable effi cacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defi c Syndr. 2005;40(4):404-412.
61. Raffi F. Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodefi ciency virus (HIV) type 1. Med Mal Infect. 2004;34(Spec No 1):8-17.